Johnson & Johnson (JNJ) News Today $160.68 +1.04 (+0.65%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 5:20 PM | markets.businessinsider.comJohnson & Johnson's Yuvanci Gets Positive CHMP Opinion In Europe For Pulmonary Arterial HypertensionJuly 26 at 5:20 PM | marketwatch.comJohnson & Johnson stock rises Friday, still underperforms marketJuly 26 at 2:49 PM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Trading Up 0.7%Johnson & Johnson (NYSE:JNJ) Shares Up 0.7%July 26 at 7:05 AM | globenewswire.comJohnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)July 26 at 7:02 AM | marketbeat.comJohnson & Johnson Q2 Earnings TranscriptJuly 26 at 12:45 AM | marketbeat.comPayden & Rygel Investment Group Takes Position in Johnson & Johnson (NYSE:JNJ)Payden & Rygel Investment Group acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 90,900 shares of theJuly 25 at 1:29 PM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Trading 1.7% Higher Johnson & Johnson (NYSE:JNJ) Shares Up 1.7%July 25 at 7:45 AM | investorplace.com3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024July 25 at 2:28 AM | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) Rating Lowered to Hold at Daiwa AmericaJuly 25 at 12:37 AM | marketbeat.comCANADA LIFE ASSURANCE Co Grows Stake in Johnson & Johnson (NYSE:JNJ)CANADA LIFE ASSURANCE Co grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,069,005 shares of the company's stock afterJuly 24 at 5:45 PM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Trading 1.1% Higher Johnson & Johnson (NYSE:JNJ) Stock Price Up 1.1%July 24 at 3:00 PM | msn.comDaiwa Capital Downgrades Johnson & Johnson (JNJ)July 24 at 11:56 AM | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) Downgraded to Neutral at Daiwa Capital MarketsJuly 24 at 10:12 AM | 247wallst.comGrab These 5 Overlooked Dividend Aristocrats Before Wall Street Catches OnJuly 24 at 8:35 AM | marketbeat.comDaiwa America Lowers Johnson & Johnson (NYSE:JNJ) to HoldDaiwa America downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday.July 24 at 7:23 AM | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) Receives $175.00 Consensus Target Price from AnalystsJuly 23 at 10:39 PM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by UniSuper Management Pty LtdUniSuper Management Pty Ltd decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 763,262 shares of the company's stock after selling 92,71July 23 at 6:53 PM | stockhouse.comJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceJuly 23 at 6:53 PM | marketwatch.comJohnson & Johnson stock underperforms Tuesday when compared to competitorsJuly 23 at 3:26 PM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Stock Price Down 1.3%Johnson & Johnson (NYSE:JNJ) Trading Down 1.3%July 23 at 1:53 PM | seekingalpha.com4 Positives For Johnson & JohnsonJuly 23 at 7:12 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Cut to Neutral at Daiwa Capital MarketsDaiwa Capital Markets lowered shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $160.00 to $150.00 in a research report on Tuesday.July 22, 2024 | marketwatch.comJohnson & Johnson stock underperforms Monday when compared to competitorsJuly 22, 2024 | marketbeat.comJohnson & Johnson (NYSE:JNJ) Trading Up 0%Johnson & Johnson (NYSE:JNJ) Stock Price Up 0%July 22, 2024 | marketbeat.comOsaic Holdings Inc. Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)Osaic Holdings Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 28.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 691,218 shares of the company's stock after selling 271,078 shares duJuly 22, 2024 | seekingalpha.comJohnson & Johnson: Seriously Undervalued At Peak PessimismJuly 22, 2024 | marketbeat.comIntuitive Surgical Stock Outperforms Market: Highs on the Horizon (JNJ)Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growingJuly 22, 2024 | businesswire.comLawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy PlanJuly 22, 2024 | nz.finance.yahoo.comJohnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionJuly 22, 2024 | benzinga.comAfter Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug CandidateJuly 22, 2024 | msn.comJohnson & Johnson Faces Legal Hurdle In Talc Lawsuit BattleJuly 22, 2024 | forbes.comShould You Pick Johnson & Johnson Stock At $155 After Q2 Beat?July 22, 2024 | businesswire.comWomen Urge Support for $8 Billion J&J Talcum Powder Settlement as July 26th Deadline ApproachesJuly 22, 2024 | prnewswire.comJohnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionJuly 22, 2024 | americanbankingnews.comFY2024 EPS Estimates for Johnson & Johnson Lifted by Analyst (NYSE:JNJ)July 21, 2024 | marketbeat.comJupiter Asset Management Ltd. Purchases Shares of 4,540 Johnson & Johnson (NYSE:JNJ)Jupiter Asset Management Ltd. bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,540 shares of the company's stock, valued atJuly 21, 2024 | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) PT Lowered to $185.00 at TD CowenJuly 21, 2024 | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) Price Target Increased to $169.00 by Analysts at Morgan StanleyJuly 21, 2024 | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) PT Lowered to $155.00July 21, 2024 | marketbeat.comJohnson & Johnson (NYSE:JNJ) Receives Average Rating of "Hold" from BrokeragesJohnson & Johnson (NYSE:JNJ - Get Free Report) has been assigned an average rating of "Hold" from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and six have issued a buy recommendJuly 21, 2024 | marketbeat.com15,740 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Councilmark Asset Management LLCCouncilmark Asset Management LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 15,740 shares of the company's stock, valued at aJuly 20, 2024 | marketbeat.comMarketBeat Week in Review – 7/15 - 7/19 (JNJ)Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves nextJuly 20, 2024 | americanbankingnews.comRoyal Bank of Canada Reaffirms Outperform Rating for Johnson & Johnson (NYSE:JNJ)July 20, 2024 | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) PT Lowered to $185.00July 20, 2024 | americanbankingnews.comJohnson & Johnson (NYSE:JNJ) Trading Down 0.1% After Analyst DowngradeJuly 19, 2024 | marketbeat.comLeo Wealth LLC Sells 283,654 Shares of Johnson & Johnson (NYSE:JNJ)Leo Wealth LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 36.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 497,915 shares of the company's stock afJuly 19, 2024 | marketwatch.comJohnson & Johnson stock underperforms Thursday when compared to competitorsJuly 19, 2024 | msn.comJNJ Earnings: Johnson & Johnson’s Q2 Results Top EstimatesJuly 19, 2024 | msn.comJohnson & Johnson (JNJ) Q2 2024 Earnings Call TranscriptJuly 19, 2024 | marketbeat.comJohnson & Johnson (NYSE:JNJ) Price Target Cut to $155.00The Goldman Sachs Group dropped their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a "neutral" rating on the stock in a research note on Friday. Get Johnson & Johnson News Delivered to You Automatically Sign up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. JNJ Media Mentions By Week JNJ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JNJ News Sentiment▼0.330.62▲Average Medical News Sentiment JNJ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JNJ Articles This Week▼5329▲JNJ Articles Average Week Get Johnson & Johnson News Delivered to You Automatically Sign up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Eli Lilly and Company News Today Merck & Co., Inc. News Today AbbVie News Today Pfizer News Today Bristol-Myers Squibb News Today Zoetis News Today Royalty Pharma News Today Jazz Pharmaceuticals News Today Perrigo News Today Corcept Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:JNJ) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Johnson & Johnson Please log in to your account or sign up in order to add this asset to your watchlist. Share Johnson & Johnson With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
